For some, the issue with GLP-1 drugs like Ozempic and Mounjaro isn't getting access to these game-changing medications, but ...

Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...

It is a slow death, admittedly, but the stench of putrefaction has already filled the air. In the United States, the diet industry is crashing and burning. Diet books are selling in much lower numbers ...

But basically it’s all about hitting the brain’s satiety centres. The new drugs make you feel full much more quickly and ...

The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday, Nov. 26, announced proposed changes in Medicare and Medicaid that would formally recognize obesity as a disease, meaning ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

NEW YORK (Reuters) - The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest prescription drugs once president-elect Donald Trump ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

The Department of Health and Human Services seeks to expand when Medicare and Medicaid can cover anti-obesity drugs, such as ...